Post Marketing Surveillance Study in Rehabilitation Clinics (Cardio, Nephro, Diabetes, Pulmo)

Boehringer Ingelheim266 enrolled

Overview

Study to obtain long-term data on effects, safety and tolerability in routine medical practice and to investigate the potential of telmisartan to prevent secondary organ damage

Study Type

OBSERVATIONAL

Enrollment

266

Conditions

Hypertension

Interventions

Micardis®DRUG

MicardisPlus®DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients of both gender aged \>=18 admitted to a hospital due to insufficiently controlled essential hypertension. No additional selection criteria have to be considered. Treatment was at the discretion of the physician following the summary of product information for Micardis® and MicardisPlus® Exclusion Criteria: * not applicable

Outcomes

Primary Outcomes

Number of patients with adverse events

Time frame: up to 1 year

Number of patients with abnormal changes in laboratory parameters

Time frame: up to 1 year

Number of patients with clinically significant changes in vital signs

Time frame: up to 1 year

Change in systolic blood pressure

Time frame: up to 1 year

Change in diastolic blood pressure

Time frame: up to 1 year

Secondary Outcomes

Global assessment of efficacy by investigator on a 4-point scale

Time frame: 2 weeks, after 1 year

Global assessment of tolerability by investigator on a 4-point scale

Time frame: 2 weeks, after 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.